Data Insights

Nogapendekin alfa by ImmunityBio for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Nogapendekin alfa by ImmunityBio for Non-Small Cell Lung Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase III for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Non-Small Cell Lung Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Renal Cell Carcinoma: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Renal Cell Carcinoma

Data Insights

Nogapendekin alfa by ImmunityBio for Metastatic Pancreatic Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Metastatic Pancreatic Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Metastatic Melanoma: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Metastatic Melanoma

Data Insights

Nogapendekin alfa by ImmunityBio for Small-Cell Lung Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Small-Cell Lung Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Hepatocellular Carcinoma: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Hepatocellular Carcinoma

Data Insights

Nogapendekin alfa by ImmunityBio for Gastric Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Gastric Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Cervical Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Cervical Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Nogapendekin alfa by ImmunityBio for Hereditary Nonpolyposis Colon Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hereditary Nonpolyposis Colon Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Hereditary Nonpolyposis Colon Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Metastatic Colorectal Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Metastatic Colorectal Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Nogapendekin alfa by ImmunityBio for Ovarian Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Ovarian Cancer

Data Insights

Nogapendekin alfa by ImmunityBio for Hereditary Nonpolyposis Colon Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hereditary Nonpolyposis Colon Cancer. According to...

Data Insights

Nogapendekin alfa by ImmunityBio for Metastatic Colorectal Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Data Insights

Nogapendekin alfa by ImmunityBio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...

Data Insights

Nogapendekin alfa by ImmunityBio for Ovarian Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Data Insights

Nogapendekin alfa by ImmunityBio for Pancreatic Cancer: Likelihood of Approval

Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Nogapendekin Alfa in Pancreatic Cancer